We approached this question in the previously described criss-cross adoptive CD8+ T-cell transfer/immunotherapy model (56, 57) by using mutant or revertant virus for donor mouse priming as well as for the infection of recipients immunocompromised by hematoablative treatment (Figure 10A). This evidence concerns the gene CD8A and infection.